Arunesh Verma Joins Fresenius Kabi USA as President
Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States
mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, has appointed Jurgen Van Broeck as Chief Executive Officer.
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
Fresenius Kabi Further Expands Oncology Portfolio
Healthcare group Fresenius tops Q4 operating profit forecast
Fresenius Launches Posaconazole Injection for Treatment of Fungal Infections
Fresenius Kabi and Mayo Clinic Enter into Agreement for Ivenix® Infusion System
Fresenius Kabi`s Biologic Idacio (adalimumab) Receives Approval in the U.S.
Fresenius Kabi Celebrates 25th Anniversary of National Blood Donation Hall of Fame by Honoring 2023 Heroes